Supreme Court Case on Script Data Sale Presents 'Gray Area' for PBM Personalized Rx Efforts
May 04, 2011
Supreme Court Case on Script Data Sale Presents 'Gray Area' for PBM Personalized Rx Efforts
A Supreme Court decision against drug developers in Sorrell v. IMS Health could potentially hamper how pharmacy benefit managers can use physician prescription data to drive adoption of pharmacogenomically guided products.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Diaceutics Report Sheds Doubt on Pharmas' Personalized Medicine Preparedness
June 15, 2011 / Pharmacogenomics Reporter - Personalized Medicine in 2012: Industry Takes a Wait-and-See Approach Due to Market Unknowns
January 9, 2013 / Pharmacogenomics Reporter - Qiagen's Experience Developing KRAS CDx for Erbitux Yields Lessons for Rx/Dx Development
November 28, 2012 / Pharmacogenomics Reporter - Dx Assays Launches Fee-for-Service CDx Development Initiative Giving Pharma More Control
November 2, 2012 / Pharmacogenomics Reporter - Dx Developers' Sales Pitch to Pharma Could be Key Factor in Marketing Some Tests
February 15, 2012 / Pharmacogenomics Reporter